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Identifying a nasal gene 
expression signature associated 
with hyperinflation and treatment 
response in severe COPD
Alen Faiz1,2,3,13, Kai Imkamp1,2,13*, Erica van der Wiel1,2, Ilse M. Boudewijn1,2, 
Gerard H. Koppelman 2,4, Corry‑Anke Brandsma 2,5, Huib A. M. Kerstjens 
1,2, Wim Timens 2,5, Sebastiaan Vroegop6, Henk R. Pasma7, Wim G. Boersma8, 
Pascal Wielders 9, Frank van den Elshout10, Khaled Mansour11, Katrina Steiling12, 
Avrum Spira12, Marc E. Lenburg12, Irene H. Heijink2,3, Dirkje S. Postma1,2 & 
Maarten van den Berge1,2
Hyperinflation contributes to dyspnea intensity in COPD. Little is known about the molecular 
mechanisms underlying hyperinflation and how inhaled corticosteroids (ICS) affect this important 
aspect of COPD pathophysiology. To investigate the effect of ICS/long‑acting β2‑agonist (LABA) 
treatment on both lung function measures of hyperinflation, and the nasal epithelial gene‑expression 
profile in severe COPD. 117 patients were screened and 60 COPD patients entered a 1‑month run‑in 
period on low‑dose ICS/LABA budesonide/formoterol (BUD/F) 200/6 one inhalation b.i.d. Patients 
were then randomly assigned to 3‑month treatment with either a high dose BDP/F 100/6 two 
inhalations b.i.d. (n = 31) or BUD/F 200/6 two inhalations b.i.d. (n = 29). Lung function measurements 
and nasal epithelial gene‑expression were assessed before and after 3‑month treatment and validated 
in independent datasets. After 3‑month ICS/LABA treatment, residual volume (RV)/total lung capacity 
(TLC)% predicted was reduced compared to baseline (p < 0.05). We identified a nasal gene‑expression 
signature at screening that associated with higher RV/TLC% predicted values. This signature, 
decreased by ICS/LABA treatment was enriched for genes associated with increased p53 mediated 
apoptosis was replicated in bronchial biopsies of COPD patients. Finally, this signature was increased 
in COPD patients compared to controls in nasal, bronchial and small airways brushings. Short‑term 
ICS/LABA treatment improves RV/TLC% predicted in severe COPD. Furthermore, it decreases the 
expression of genes involved in the signal transduction by the p53 class mediator, which is a replicable 
COPD gene expression signature in the upper and lower airways.
Trial registration: ClinicalTrials.gov registration number NCT01351792 (registration date May 11, 
2011), ClinicalTrials.gov registration number NCT00848406 (registration date February 20, 2009), 
ClinicalTrials.gov registration number NCT00158847 (registration date September 12, 2005).
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Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of death  worldwide1. The presence and 
severity of COPD is generally documented by a decreased forced expiratory volume in 1 s  (FEV1) and  FEV1/
forced vital capacity (FVC) ratio that is not (fully) reversible with  bronchodilation2. In addition, air trapping is 
present in a considerable proportion of patients, as reflected by an increased residual volume (RV) in relation to 
total lung capacity (TLC). This trapped air, i.e. hyperinflation that is associated with heterogeneity in patency of 
the small airways, contributes importantly to the dyspnea intensity experienced by COPD  patients3.
COPD is characterized by an abnormal inflammatory response in the airways and lungs to inhaled noxious 
gases and  particles4,5. The inflammation in COPD occurs in the central and peripheral airways and lung paren-
chyma. A number of mechanisms can link inflammation and hyperinflation in  COPD6. Inflammation of the 
airways is associated with (1) oedema which can contribute to increased airway resistance in large and small 
airways; (2) neutrophil infiltration that is related a.o. to increased oxidative stress, and cytokine and elastase 
release that associate with airway wall fibrosis and mucus production/plugging7 and (3) emphysema contribut-
ing to the loss of elastic recoil and (small) airway collapse at  expiration8. All these components contribute to 
lung hyperinflation. Little is known about the molecular mechanisms driving the cellular actions in airways and 
lung parenchyma, underlying the complex pathophysiology of hyperinflation. Inflammation likely contributes 
to hyperinflation since it has been shown that the ICS fluticasone, with and without LABA treatment can reduce 
hyperinflation in  COPD9,10. One of the cell types directly affected by ICS are epithelial cells aligning the airway 
walls as a direct barrier against inhaled toxic  substances11. Epithelial cells contribute to inflammation by produc-
ing pro-inflammatory cytokines and mediators during exposure to inhaled toxic particles. Smoking has been 
shown to affect the gene-expression profile in upper and lower airways comparably, suggesting that one may use 
nasal epithelial brushes as a non-invasive marker for the lower  airways12.
The study was originally designed to compare the effect of beclomethasone/formoterol (BDP/F) to budeso-
nide/formoterol (BUD/F) treatment in patients with severe COPD and hyperinflation. However, the study was 
terminated prematurely due to slow inclusion and was thus underpowered. Therefore, we grouped the two treat-
ment arms to analyze the effects of treatment on RV% predicted at day 84 (3 months). As a secondary outcome, 
we investigated  FEV1%, TLC% and RV/TLC% predicted. Finally, we performed genome-wide gene-expression 
profiling in the nasal epithelium to identify a gene-expression signature related to hyperinflation in COPD.
Methods
Patient population. The “A 12-week, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm 
Parallel Group Study Comparing the Efficacy and Safety of  Foster® 100/6 (Beclomethasone Dipropionate 100 µg 
Plus Formoterol 6 µg/Actuation), 2 Puffs b.i.d., Versus  Symbicort® 200/6 (Budesonide 200 µg Plus Formoterol 
6 µg/Actuation), 2 Inhalations b.i.d., on Parameters of Small Airway Function in Patients With Chronic Obstruc-
tive Pulmonary Disease” (FAIR) study (registered as NCT01351792 registration date May 11, 2011) included 
COPD patients when they fulfilled the following inclusion criteria: age ≥ 40 years, a post-bronchodilator FEV1/
FVC < 0.7 and  FEV1 < 50% of the predicted normal value, and a smoking history of at least 10 pack-years, regu-
lar use of bronchodilators, a Functional Residual Capacity (FRC) > 120% of predicted, and a Baseline Dyspnea 
Index (BDI) total score ≤ 10. We excluded patients with a diagnosis of asthma or other clinically or functionally 
relevant respiratory disorders (other than COPD). The online supplement presents further details on eligibility 
criteria. Patients were recruited between September 2011 and February 2013 from different centers in the Neth-
erlands: University Medical Center Groningen (UMCG), Medical Center Leeuwarden, Martini Hospital Gron-
ingen, Medical Center Alkmaar, Catharina Hospital Eindhoven, Rijnstate Hospital Arnhem and Orbis Concern 
Sittard.
A graphical overview of the study is presented in Fig. 1. After inclusion, all patients entered a 1-month run-in 
period during which their current inhaled treatment was switched to a low dose Symbicort Turbuhaler 200/6 one 
inhalation b.i.d. (budesonide 200 µg plus formoterol 6 µg/actuation dry powder inhalation (BUD/F), AstraZen-
eca, London, UK Limited) with as needed salbutamol pressurized metered dose inhaler (pMDI) 100 µg and/or 
ipratropium bromide 20 µg (pMDI). No other inhaled medications or oral prednisolone were allowed during 
the study. After the run-in period, patients were randomly assigned to a 3-month treatment period with Foster 
100/6 two inhalations b.i.d. (beclomethasone dipropionate 100 µg plus formoterol 6 µg/actuation pressurized 
metered dose inhaler (BDP/F)), Chiesi Pharmaceutici S.p.A., Parma, Italy) or BUD/F 200/6, two inhalations 
b.i.d. Lung function measurements and body plethysmography were performed at screening (month − 1), at 
baseline, and after 1 and 3 months of treatment. Nasal epithelial brushes (CYTO-PAK Cytosoft Brush CP-5B, 
Figure 1.  Schematic diagram of FAIR study outline.
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Medical Packaging Corp., Camarillo, USA), were taken at screening (month − 1), at baseline, and after 3 months 
of treatment. The methods for mRNA isolation, labelling, microarray hybridization (Affymetrix_HuGene_ST1.0 
Array) and quality control were conducted as previously  described13. The study was approved by the medical 
ethics committee in Groningen and all subjects gave their written informed consent. All methods were performed 
in accordance with the relevant guidelines and regulations. The between groups comparison originally planned 
lacks of statistical power. Nevertheless, collected data are valuable for the purpose of the genome-wide gene-
expression profiling and for the investigation of ICS/LABA treatment effect on hyperinflation.
Statistical analysis. In brief, the lung function changes with treatment were analyzed using a linear mixed 
effects model with time defined as a categorical variable with three levels (0 = baseline, 1 = after 1-month, 3 = after 
3-month ICS/LABA treatment), treatment defined as a categorical variable with two levels. To analyze individual 
time-points, a paired Student’s t-test was used. All analyses were done in SPSS (version 22).
Gene‑expression analyses in the FAIR study. Gene-expression data analysis was conducted using the 
statistical package R (version 3.2.2). We investigated the association between nasal epithelial gene-expression 
and RV/TLC% predicted at screening of patients in the FAIR study (n = 76). To this end, a linear regression anal-
ysis was performed adjusting for smoking status as a possible confounder.  Geij represents the log2 gene expres-
sion value for a gene in sample i from patient j, ɛij represents the error that is assumed to be normally distributed:
Genes increased with higher RV/TLC% predicted will be hence forth referred to as the hyperinflation gene-
expression signature. The model used for the gene-expression analyses are explained in detail in the online 
supplementary materials. A false discovery rate (FDR) < 0.25 calculated using the Benjamini Hochberg (BH) 
correction was used for all analyses.
Comparison of the hyperinflation gene‑expression signature to the lower airways. We next 
compared the hyperinflation gene-expression signature in nasal epithelium to a RV/TLC% predicted signature 
generated in bronchial biopsies in the Groningen and Leiden Universities study of Corticosteroids in Obstruc-
tive Lung Disease (GLUCOLD)  study13. The GLUCOLD study recruited male and female patients from family 
practices in Groningen and Leiden in the Netherlands. Exclusion criteria included asthma history or diagnosis 
and inhaled corticosteroid use within 6 months prior to randomization. Patients were randomly assigned to one 
of four treatment arms:
1. 6-month fluticasone propionate 500 μg b.i.d. followed by placebo for 24 months.
2. 30-month fluticasone propionate 500 μg b.i.d.
3. 30-month combination therapy with fluticasone/salmeterol 500/50 μg b.i.d.
4. 30-month placebo.
In all patients, a spirometry was performed every 3 months. In addition, bronchoscopy with endobron-
chial biopsies, sputum induction, and methacholine challenge were performed at 0, 6 and 30 months. During 
bronchoscopy, six macroscopically adequate bronchial biopsy specimens were immediately fixed in 4% neutral 
buffered formalin for 24 h, then processed and embedded in paraffin, and two biopsies were immediately snap 
frozen and stored at − 80 °C for RNA studies. Of the 114 patients enrolled, 101 were treatment-compliant. Of 
these, 88 and 77 have snap frozen biopsies available for two-time points (baseline and 6 months) or three-time 
points (baseline, 6 months and 30 months).
A linear model was used to compare association between gene expression and RV/TLC% predicted correcting 
for current smoking status. The t-statistic generated from this analysis was used to rank the genes associated with 
RV/TLC in the lower airways. Gene set enrichment analysis (GSEA) (v 2.2.2) was used to compare this ranked list 
to the hyperinflation gene-expression signature generated in the nose. For all GSEA analyses, a false-discovery 
rate threshold of FDR less than 0.05 was used to determine significant enrichment.
Comparison of the hyperinflation gene‑expression signature between COPD patients and 
non‑COPD controls. To compare nasal epithelium from COPD patients to non-COPD controls, a sub-
set of the COPD patients included in the FAIR study collected at the UMCG (at screening), were compared 
to nasal epithelium of age matched healthy patients collected at the same location during the same time as 
part of the Study to Obtain Normal Values of Inflammatory Variables From Healthy Subjects (NORM) study 
(NCT00848406). In the NORM study, healthy smokers and never-smokers were included, defined by an absence 
of respiratory symptoms (no bronchial hyperresponsiveness to methacholine and a normal spirometry with 
 FEV1/FVC > 70% and  FEV1 > 80% predicted). All nasal brushes were extracted and run on Affymetrix-Hugene-
st1.0 arrays at the same time to minimize technical variation between the studies. A linear model was used to 
compare COPD and healthy controls correcting for age, gender and current smoking status. The t-statistic gen-
erated from this analysis was used to rank the genes associated with COPD. The hyperinflation genes were com-
pared with these ranked genes. This analysis was repeated in two additional COPD related signatures from both 
the large and small airways using two publically available independent datasets (GSE37147 and GSE56341)14,15.
Large airway epithelium. To examine whether the hyperinflation gene-expression signature was associ-
ated with the presence of COPD in large airway bronchial brushes, we utilized a dataset which we have previ-
Geij = β0 + β1XSmoking Status−i + β2XRV/TLC% predicted−i + εij
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ously published of large airway bronchial brushes from COPD and non-COPD patients (GSE37147)14. Using 
spirometry measurements obtained within 1 year of bronchoscopy, COPD was defined as the presence of both 
an FEV1/FVC ≤ 0.7 and FEV1% predicted < 80. The data was analysed comparing COPD to non-COPD using 
a linear model adjusting for age, gender, smoking status (current or former smoker), and cumulative tobacco 
exposure (calculated for the time of bronchoscopy). Genes were ranked according to the generated t-statistic 
from this analysis, then GSEA was used to compare this ranked list to the hyperinflation gene-expression sig-
nature.
Small airway epithelium. To examined whether the hyperinflation gene-expression signature was associ-
ated with the presence of COPD in small airway bronchial brushes, we utilized a publically available dataset of 
small airway bronchial brushes from COPD patients (GOLD stage II and III) and healthy controls (GSE56341)15. 
Raw data was obtained from the Gene Expression Omnibus (GEO) and was normalized using RMA. Data was 
analyzed using limma comparing COPD patients (GOLD stage II and III) to healthy controls in small airway 
brushings. Genes were ranked according to the generated t-statistic from this analysis, then GSEA was used to 
compare this ranked list to hyperinflation gene-expression signature.
Comparison of the hyperinflation gene‑expression signature with ICS/LABA treatment. Next, 
we investigated whether the hyperinflation gene-expression signature was altered during ICS/LABA treatment. 
To this end, we compared gene-expression changes after increasing the relative dose of ICS/LABA treatment 
(BDP/F and BUD/F combined) in the FAIR study (baseline compared the 3-months), using a linear mixed effect 
model. The model was adjusted for smoking status, age and gender as possible confounders. The t-statistic gener-
ated from this analysis was used to rank the genes associated with changes in expression during 3 months high 
dose ICS/LABA. GSEA was used to compare this ranked list to the hyperinflation gene-expression. Finally, to 
verify the above analysis in the lower airways we investigated how the hyperinflation gene-expression signature 
responded to 6-months ICS or ICS/LABA compared to placebo in bronchial biopsies (GLUCOLD). A linear 
mixed effect model was conducted comparing the interaction between the change in expression over 6 month 
treatment of ICS or ICS/LABA to placebo, adjusting for smoking status, age and gender as possible confound-
ers. The t-statistic generated from this analysis was used to rank the genes associated with changes in expression 
during 6 months ICS/LABA or ICS compared to placebo. GSEA was used to compare this ranked list to the 
hyperinflation gene-expression.
Pathway analysis. Pathway analysis was conducted using Gene Network analysis. This pathway analysis 
software uses an independent gene expression dataset of ~ 78,000 samples to predict the function of genes in an 
unbiased way. We used this method to predict (currently unknown) gene functions based on known biological 
pathways available in the molecular signatures database MSigDB (https ://www.broad insti tute.org)16.
Results
Patient demographics. One hundred and seventeen patients entered the screening period from whom 
nasal epithelial brushes were available in 76 cases. Because the strict inclusion criteria accounted for a much 
higher than expected screening failure rate and a much lower than planned recruitment pace, the FAIR study 
was terminated prematurely resulting in lower numbers than expected for each treatment group. A total of 60 
COPD patients were randomized, with 29 patients assigned to BDP/F and 31 patients to BUD/F. After randomi-
zation, 20 patients dropped out due to an exacerbation and 40 completed the study. A total of 57 out of the 60 
randomized COPD patients had upper airway epithelial brushes available at one or more time points with RNA 
of sufficient quality.
The effect of increasing the dose of ICS/LABA treatment on lung function parameters over 
the course of 3 months. We found no significant effect of increasing the dose of ICS/LABA treatment on 
pre- and post-dose RV% predicted (the primary end point measured in this clinical trial), TLC% predicted, and 
 FEV1% predicted over the 3-month treatment period (Fig. 2A–C). However, pre-dose RV/TLC% predicted sig-
nificantly improved compared to baseline following 3-month treatment (Fig. 2D, p < 0.05). Interestingly, when 
analyzing the individual time points (paired Student’s t-test) we did not find any changes after 1 month but did 
so after 3 months, suggesting that a longer period of treatment is required for the improvement in RV/TLC% 
predicted to occur. This improvement in RV/TLC% predicted after 3-months of treatment was not accompanied 
by a significant improvement of clinical symptoms measured by CCQ scores and Transition Dypsnae Index 
(TDI) (Table 1).
Associations between upper airway gene‑expression and hyperinflation. We identified 140 
genes for which the expression in nasal epithelium was increased with more severe hyperinflation as measured 
by RV/TLC% predicted and 4 genes for which expression was decreased (n = 76, FDR < 0.25). A list of the top 50 
genes is presented in Table 2. Figure 3 shows a heatmap of the 144 genes associated with RV/TLC% predicted 
with patients ordered based on the severity of hyperinflation.
The hyperinflation signature in the upper airways is representative of the gene‑expression 
signature related to hyperinflation in the lower airways. In order to evaluate whether the hyperin-
flation gene-expression signature in the nasal epithelium is representative for the lower airways, we performed 
a GSEA on gene-expression data derived from bronchial biopsies of COPD patients who participated in the 
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GLUCOLD  study13. Their clinical characteristics are summarized in Table 3. Figure 4A shows a strong overlap 
between genes increased with RV/TLC% predicted in nasal epithelium and genes increased with RV/TLC% 
predicted in bronchial biopsies (GSEA p < 0.05).
Relationship between the hyperinflation gene‑expression signature and presence of COPD 
throughout the respiratory tract. We next examined whether the hyperinflation gene-expression sig-
nature was associated with the presence of COPD in both the nasal and lower airway epithelium. To run this 
Figure 2.  Influence of ICS/LABA (BDP/F and BUD/F treatment arms combined) on measures of 
hyperinflation and lung function. Lung function measurements were taken before study medication at baseline, 
1 month and 3 months. (A)  FEV1% predicted, (B) RV% predicted (C) TLC% predicted (D) RV/TLC% predicted 
and E) FEF 25–75% predicted. Linear mixed effects model comparing each time point. *p < 0.05  FEV1, forced 
expiratory volume in one second; RV, residual volume; TLC, total lung capacity; RV/TLC, residual volume/total 
lung capacity; FEF 25–75% predicted, the average forced expiratory flow during the mid (25–75%) portion of 
the FVC. All data are expressed as mean ± SEM.
Table 1.  Patient characteristics (BDP/F and BUD/F combined). Lung function measurements were taken 
before and 2 h after study medication at screening, baseline, 1 month and 3 months. Student paired T-test 
compared to baseline * < 0.05.  FEV1, forced expiratory volume in one second; RV, residual volume; TLC, 
total lung capacity; RV/TLC, residual volume/ total lung capacity; CCQ, Clinical COPD Questionnaire; BDI, 
Baseline Dyspnea Index, TDI, Transition Dyspnea Index. All data are expressed as mean ± SD.
Screening Baseline Month 1 Month 3
Number of patients 117 60 50 40
Male/female, n 83/34 44/16 39/11 31/9
Age, years 63.1 (8.7) 62.1 (8.5) 62.9 (8.6) 62.8 (8.9)
BMI kg/m2 25.5 (4.7) 24.8 (3.8) 24.9 (3.5) 24.8 (3.7)
Current smokers, n (%) 39 (33) 21 (35) 17 (34) 14 (35)
FEV1% predicted pre 34.3 (7.8)
30.6 (6.0) 32.1 (7.3) 31.5 (6.8)
Post 2 h 37.9 (8.3) 37.4 (8.2) 36.7 (7.6)
RV% predicted pre
211.9 (58.8)
215.2 (49.6) 212.7 (53.0) 203.5 (51.9)
Post 2 h 187.4 (47.7) 191.8 (50.9) 188.1 (51.2)
TLC% predicted pre
127.3 (20.5)
126.0 (16.9) 125.1 (17.3) 123.7 (16.9)
Post 2 h 122.6 (17.0) 123.9 (17.9) 123.3 (17.6)
RV/TLC% predicted pre
152.4 (23.6)
157.8 (21.0) 156.7 (22.7) 151.1 (22.9)*
Post 2 h 140.9 (22.4) 142.4 (22.5) 140.3 (22.9)
CCQ 1.95 (0.79) 2.04 (0.87)
BDI/TDI 6.04 (1.61) 0.08 (2.53)
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analysis in the (i) nasal epithelium, a subset of COPD nasal gene expression profiles from the FAIR study were 
compared to age matched healthy subjects from the NORM study; while the comparisons between COPD and 
non-COPD controls in the (ii) large and (iii) small airways was conducted in two publically available datasets 
(GSE37147 and GSE56341)14,15. By GSEA, we found similar enrichment of the hyperinflation gene-expression 
Table 2.  List of top 50 genes associated with RV/TLC% predicted (FDR < 0.25).
Gene T value P value FDR
RLN1 − 3.759 0.000347 0.189
ABHD16A 3.645 0.000506 0.195
TMEM104 3.648 0.000501 0.195
SLC22A18 3.649 0.000499 0.195
SLC6A6 3.657 0.000487 0.195
SIK3 3.669 0.000468 0.195
USP5 3.669 0.000468 0.195
TAB1 3.671 0.000464 0.195
LDOC1L 3.691 0.000434 0.195
ZNF142 3.694 0.00043 0.195
ABCB6 3.696 0.000427 0.195
PAK6 3.699 0.000424 0.195
SRRM2 3.719 0.000396 0.195
KHSRP 3.745 0.000364 0.189
HCFC1 3.752 0.000355 0.189
SMARCA4 3.777 0.000327 0.184
VAC14 3.785 0.000319 0.184
CTSD 3.798 0.000304 0.182
ATP13A1 3.828 0.000275 0.170
CBX6 3.847 0.000258 0.164
BAG6 3.850 0.000256 0.164
RPTOR 3.860 0.000248 0.164
PPRC1 3.861 0.000246 0.164
CARM1 3.863 0.000245 0.164
ALDOA 3.875 0.000235 0.164
SEPT9 3.891 0.000223 0.164
ARF3 3.922 0.000201 0.164
ATF6B 3.925 0.000198 0.164
WDR18 3.943 0.000186 0.164
ATN1 3.963 0.000174 0.164
DAG1 3.980 0.000164 0.162
UBE2O 3.985 0.000161 0.162
VARS 3.995 0.000156 0.162
TNPO2 4.043 0.000132 0.154
MECP2 4.065 0.000123 0.151
PRRC2A 4.093 0.000111 0.146
DNMBP 4.120 0.000101 0.142
PCNXL3 4.131 9.72E−05 0.142
MYH14 4.134 9.64E−05 0.142
EXOC7 4.134 9.63E−05 0.142
MINK1 4.169 8.53E−05 0.142
MEPCE 4.172 8.43E−05 0.142
MAVS 4.236 6.72E−05 0.142
SAMD4B 4.277 5.80E−05 0.142
UBA1 4.380 4.02E−05 0.132
RNF123 4.441 3.22E−05 0.127
GEMIN4 4.497 2.62E−05 0.127
ANKRD52 4.608 1.75E−05 0.115
G6PD 4.726 1.13E−05 0.111
SRCAP 4.806 8.34E−06 0.111
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signature among genes increased with COPD compared to non-COPD in upper, large and small airway epithe-
lial brushings (all GSEA p < 0.05, Fig. 4B–D).
Interestingly, we found a large overlap of the core enriched genes associated with our hyperinflation gene-
expression signature in all three compartments of the airways indicating a common signature throughout the res-
piratory tract (Fig. 4E,F). Table 4 shows an overview of the principal characteristics from the main datasets used. 
The effect of ICS/LABA treatment on the hyperinflation gene‑expression signature. To evalu-
ate whether the ICS/LABA treatment alters genes related to hyperinflation, we performed a GSEA on the change 
of gene-expression associated with doubling the dose of ICS/LABA (BDP/F and BUD/F groups combined), 
between baseline and 3 months treatment. Figure 4A shows that genes increased with hyperinflation were sig-
nificantly enriched among genes that were decreased by doubling the dose of ICS/LABA (GSEA p < 0.05).
To validate the above hypothesis in the lower airways the hyperinflation gene-expression signature was subse-
quently investigated in the GLUCOLD study where genome-wide gene-expression data was available in bronchial 
biopsies from COPD patients before and after 6-month treatment with ICS (Fluticasone) ± LABA (Salmeterol) 
compared to placebo. The ICS/LABA and ICS arms were compared to placebo independently to distinguish the 
overall effect of ICS from the combined treatment. Figure 5B demonstrates that genes increased with hyperin-
flation in nasal epithelium (FAIR study) were significantly enriched among genes that were decreased by ICS/
LABA compared to placebo in the bronchial biopsies (GLUCOLD study, GSEA p < 0.05), mirroring the results 
seen in nasal epithelium. Finally, 6-month treatment with ICS compared to placebo revealed similar results as 
ICS/LABA (GSEA p < 0.05), suggesting ICS treatment affected the hyperinflation gene-expression profile in the 
absence of LABA (Fig. 5C). Figure 5D shows a heatmap of the genes in the hyperinflation gene-expression profile 
which were core enriched among genes decreased in both the ICS and ICS/LABA treatment groups compared to 
placebo. We found a large overlap of the core enriched genes associated with our hyperinflation gene-expression 
signature in all three treatment groups in the airways indicating a common subset of hyperinflation related genes 
which are repressed by ICS ± LABA treatment in both the upper and lower airways (Fig. 5E,F).
Figure 3.  Nasal gene-expression associated with RV/TLC% predicted. Heatmap of genes associated with RV/
TLC% predicted at baseline in all screened patients with severe COPD (FDR < 0.25).
Table 3.  GLUCOLD patient characteristics. FEV1, forced expiratory volume in one second; RV/TLC, residual 







N 21 19 18 21
Male/female 18/3 16/3 15/3 17/4
Age (years), mean (SD) 63.7 (7.6) 60.8 (7.9) 60.8 (8.6) 58.4 (8.1)
Current smokers, N 10 10 12 14
FEV1% pred, mean (SD) 64.7 (8.6) 65.2 (8.5) 61.9 (9.6) 61.3 (8.8)
RVTLC % pred 124.7 (19.1) 120.1 (18.6) 126.4 (19.3) 125.2 (16.9)
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Pathway analysis. Pathway analysis was conducted on the hyperinflation gene-expression profile during 
screening. This analysis identified that “DNA damage response, signal transduction by p53 class mediator result-
ing in induction of apoptosis” and “histone deacetylation” pathways were increased with increasing severity of 
hyperinflation. The list of the top 10 pathways is displayed in Table 5.
Figure 4.  The relationship between the hyperinflation gene expression signature and presence of COPD in 
the upper, large and small airway brushings. (A) Enrichment of genes increased with RV/TLC% predicted 
in the upper airway among genes increased with RV/TLC% in bronchial biopsies (p < 0.001). The color bar 
indicates the genes ranked according to their association with RV/TLC% predicted in bronchial biopsies 
(blue representing a negative association with RV/TLC% predicted and red indicating a positive association). 
Enrichment of genes increased with RV/TLC% in the nose among genes increased in COPD (B) nasal 
epithelium, (C) large airway brushings and (D) small airway brushings, compared to healthy controls 
(GSEAp < 0.001). The color bar indicates the genes ranked according to their expression in COPD epithelial cells 
compared to healthy/non-COPD controls (blue representing genes decreased in COPD epithelium compared 
to healthy/non-COPD controls, while red indicates an increase in epithelial gene-expression). (E) Heatmap 
of rank metric score of the hyperinflation signature GSEA in comparison to the upper, large and small airway 
brushing from COPD and non-COPD controls. The enrichment of genes in the hyperinflation signature among 
genes increased in COPD in the upper, large and small airway brushing is represented with the green scale and 
illustrated in a (F) Venn diagram.
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Discussion
In this randomized double-blind study, increasing the equivalent dose of ICS/LABA did not improve  FEV1. 
However, it did improve hyperinflation as reflected by RV/TLC% predicted, while it took up to 3 months for 
the effect to occur. Furthermore, we identified a nasal epithelial gene-expression signature that associated with 
hyperinflation as reflected by RV/TLC% predicted and validated this signature in bronchial biopsies of an inde-
pendent cohort of patients with mild-to-moderate COPD. Finally, we found this signature to be increased in 
COPD, both in epithelium derived from the upper airways, and of the lower large and small airways, indicating 
a common signature associated with hyperinflation throughout the respiratory tract. Our study suggests that this 
nasal epithelial gene-expression profile can serve as a non-invasive biomarker of the severity of hyperinflation 
in COPD as reflected by RV/TLC% predicted.
We found this hyperinflation associated nasal gene expression signature to be dynamic with ICS/LABA 
treatment in COPD. Furthermore, this change was concordant in the lower airways after ICS/LABA treatment 
in an independent study using bronchial biopsies. Genes involved in p53-mediated apoptosis were particularly 
enriched in this hyperinflation signature.
When analyzing the nasal gene-expression signature in an independent dataset of bronchial biopsies derived 
from the lower large airways of patients with COPD, we found a similar association with the severity of hyper-
inflation, even though the degree of hyperinflation in this cohort of patients wild mild-to-moderate COPD 
was on average less. This observation is compatible with the field-of-injury hypothesis put forward by Gower 
et al., proposing that inhalation of environmental ‘inhaled exposures can elicit a common molecular response 
throughout the respiratory tract’12.
We did not find an improvement in  FEV1% predicted, with 3-month ICS/LABA treatment. However, we did 
find a statistically significant improvement in RV/TLC% predicted with 3-month treatment. This improvement 
was not present after 1-month of treatment, suggesting that a treatment for a longer period is required before an 
effect can be seen. Similar to our findings, O’Donnell et al. showed an improvement in hyperinflation, as reflected 
by RV and Forced Respiratory Capacity (FRC), following treatment with fluticasone/salmeterol for 2 months, 
while John et al. showed a significant decrease in RV/TLC% predicted after 3-month treatment with extra-fine 
particle  beclomethasone9,10. Further, larger-sized studies have to assess whether either short-term treatment with 
small or large particle ICS/LABA combination, or ICS alone, differentially affect hyperinflation. Also, it should 
be evaluated whether the effect of ICS treatment continues to improve with longer duration.
We established that the RV/TLC% predicted gene-expression signature is different in COPD patients com-
pared to healthy controls. This was the case not only in the upper, but also the large and small airway epithelium, 
providing suggestive evidence that the identified genes are not only relevant to hyperinflation per se, but also to 
COPD pathogenesis. However, given the cross-sectional nature of our study we do not elucidate whether this is 
a cause or consequence of hyperinflation or a coincidental finding by a common pathogenetic mechanism lead-
ing to increased severity of hyperinflation. Prospective studies in less severe COPD patients have to reveal this.
Interestingly, we show that the gene-expression signature for hyperinflation was enriched among genes that 
were affected after doubling the dose of ICS/LABA. Analysis of an independent study of bronchial biopsies 
showed that 6-month treatment with ICS on the hyperinflation signature provided comparable results in gene-
expression as ICS/LABA  combination13, which may suggest that the response was mainly driven by the ICS 
component rather than the LABA component. As ICS treatment was found to inhibit the expression of p53 
pathway genes collectively in the current study, our results suggest that ICS may inhibit smoke-induced apoptosis 
by repressing the p53 pathway. Alternatively, ICS may have an effect on (epithelial) genes that affect inflammation 
 indirectly13. Reduction of peripheral inflammation can contribute to the reduction of small airways narrowing 
and reduction in peribronchiolar inflammation in improvement of peribronchial contractile forces, all leading 
to improvement of hyperinflation. Our findings suggest that the nasal gene expression signature identified in 
this study may be used as a biomarker for changes in inflammation which result in improvement in RV/TLC% 
predicted.
One of the main strengths of this study is the use of independent cohorts (1) to validate the gene-expression 
signature associated with RV/TLC% predicted as found in the nose in the signature present in the large airways 
(GLUCOLD) and (2) to confirm that this signature was differentially expressed in COPD both in upper airway 
epithelium and throughout the respiratory tract. Furthermore, our study consists of a unique cohort of patients 
Table 4.  Principal characteristics from the main datasets used (FAIR, GLUCOLD, NORM). All data are 
expressed as mean ± SD. FEV1, forced expiratory volume in one second; RV, residual volume; TLC, total lung 
capacity; RV/TLC, residual volume/ total lung capacity.
FAIR GLUCOLD NORM
Number of patients, n 60 79 77
Male/female, n 44/16 66/13 41/36
Age, years 62.1 (8.5) 60.9 (8.1) 36.1 (16.2)
Current smoker, n (%) 21 (35%) 46 (58%) 41 (53.2%)
FEV1% predicted 37.9 (8.3) 63.3 (8.9) 108.1 (10.5)
RV % predicted 187.4 (47.7) N/A 93.7 (17.5)
TLC % predicted 122.6 (17.0) N/A 104.0 (9.4)
RV/TLC % predicted 140.9 (22.4) 124.1 (18.5) 85.6 (12.4)
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with both severe COPD and a significant degree and broad range of hyperinflation. There are some limitations 
to this study. The subgroups of current and former smokers were too small to do independent analysis on the 
influence of smoking status on both the response to ICS/LABA therapy and nasal gene expression. Furthermore, 
we were unable to directly compare the nasal and small airways gene-expression profile in the same patients due 
to technical difficulties obtaining samples from the lower airways in severe COPD. However, we were able to show 
that our hyperinflation signature was increased in independent large and small airway epithelial bushings from 
mild-to-moderate COPD patients, providing evidence that this signature is altered throughout the respiratory 
tract. Another limitation is the lenient FDR < 0.25 that we used to identify our hyperinflation gene-signature in 
the nasal epithelium. Despite this fact, our signature was associated with RV/TLC% predicted in independent 
Figure 5.  Gene set enrichment analysis (GSEA) comparison of genes associated with RV/TLC% predicted 
in bronchial biopsies (GLUCOLD). (A) Enrichment of genes increased with RV/TLC% predicted in the nose 
among genes down-regulated in nasal epithelium following increased dosage with ICS/LABA (p < 0.001) or 
treatment with (B) ICS/LABA (fluticasone/salmeterol) (p < 0.001) and (C) solely ICS (fluticasone) (p < 0.001) 
for 6 months compared to placebo in bronchial biopsies. The color bar indicates the genes ranked according 
to their change in expression with ICS (blue representing a treatment-induced decrease and red an increase in 
gene-expression). The vertical bars in all plots indicate the genes increased with RV/TLC% predicted with the 
location of the bar indicating the occurrence of that gene within the ranked gene list and the height of the bars 
indicating the running GSEA enrichment score (black bars = core enriched genes, grey bars = core non-enriched 
genes). (D) Heatmap of the change of expression of genes associated with RV/TLC% predicted core enriched 
to be decreased in bronchial biopsies from patients with COPD after 6 months treatment with ICS/LABA 
(fluticasone/salmeterol) or solely ICS (fluticasone). (E) Heatmap of rank metric score of the RV/TLC signature 
GSEA comparison to increased dosage with ICS/LABA (p < 0.001) in nasal epithelium, and treatment with 
ICS/LABA (fluticasone/salmeterol) or solely ICS (fluticasone) compared to placebo in bronchial biopsies. The 
enrichment of genes in the RVTLC signature among genes decreased within the three datasets is represented in 
the green scale and illustrated in a (F) Venn diagram.
11
Vol.:(0123456789)
Scientific Reports |        (2020) 10:17415  | https://doi.org/10.1038/s41598-020-72551-0
www.nature.com/scientificreports/
dataset of large airway bronchial biopsies from mild-to-moderate COPD patients, demonstrating the robustness 
of this signature. Finally, as a placebo arm was not included in this study, we were unable to account for a placebo 
effect on the clinical measurements in this study.
Conclusion
In summary, treatment with ICS/LABA in patients with severe COPD decreased hyperinflation as measured by 
RV/TLC% predicted after 3-month treatment. This improvement in hyperinflation was not accompanied by an 
improvement in respiratory symptoms. We did not find any change after 1 month of ICS/LABA treatment, sug-
gesting that a longer treatment period is required for the improvement to occur. Further, we have identified and 
validated a gene-expression signature that is associated with RV/TLC% predicted in upper airway epithelium 
from patients with severe COPD, a clinically relevant phenotype that drives dyspnea in COPD. We found this 
signature to associate with increased p53 mediated apoptosis. Since ICS/LABA treatment improves RV/TLC% 
predicted and shifts the associated gene-expression signature towards normal, our findings provide a clear gene 
signature associated with ICS-induced clinical improvement in RV/TLC% predicted in COPD.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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Table 5.  Pathway analysis. List of the top 10 pathways associated with the hyperinflation gene signature.
Pathway or process p-value
Signal transduction by p53 class mediator resulting in induction of apoptosis 1 × 10–27
DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis 1 × 10–26
Histone deacetylation 4 × 10–26
Protein targeting 3 × 10–22
Regulation of histone deacetylation 5 × 10–22
Positive regulation of protein deacetylation 1 × 10–21
Protein deacetylation 7 × 10–21
In utero embryonic development 3 × 10–20
Regulation of protein deacetylation 5 × 10–20
rRNA transcription 7 × 10–20
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